A5000621664- Bladder and Urothelial Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Urinary and Genital Oncology Studies
- Prostate Cancer Treatment and Research
- Genital Health and Disease
- Renal and related cancers
- Economic and Financial Impacts of Cancer
- Health Systems, Economic Evaluations, Quality of Life
- Urologic and reproductive health conditions
- Urological Disorders and Treatments
- Cancer Genomics and Diagnostics
- Radiopharmaceutical Chemistry and Applications
- Radiomics and Machine Learning in Medical Imaging
- Esophageal Cancer Research and Treatment
- Statistical Methods in Clinical Trials
- Eosinophilic Esophagitis
- Lung Cancer Treatments and Mutations
- Pancreatic and Hepatic Oncology Research
- Multiple and Secondary Primary Cancers
- Sarcoma Diagnosis and Treatment
- Prostate Cancer Diagnosis and Treatment
- Colorectal and Anal Carcinomas
- Frailty in Older Adults
- Cancer survivorship and care
European Association of Urology
2022-2025
Royal Marsden NHS Foundation Trust
2023-2025
IRCCS Ospedale San Raffaele
2021-2024
Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele
2022-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2019-2024
Vita-Salute San Raffaele University
2021-2024
Royal Marsden Hospital
2023-2024
Institute of Experimental Endocrinology of the Slovak Academy of Sciences
2024
Fondazione IRCCS Istituto Nazionale dei Tumori
2019-2023
Institute of Cancer Research
2023
Immune checkpoint inhibitors (ICIs) have revolutionised cancer therapy but frequently cause immune-related adverse events (irAEs). Description of late-onset and duration irAEs in the literature is often incomplete.To investigate reporting incidence long-lasting irAEs, we reviewed all registration trials leading to ICI's approval by US FDA and/or EMA up December 2019. We analysed real-world data from lung (LC) melanoma (Mel) patients treated with approved ICIs at University Hospital Lausanne...
Abstract Purpose: The PURE-01 study (NCT02736266) pioneered the neoadjuvant immune-checkpoint inhibitor (ICI) therapy before radical cystectomy (RC) in patients with muscle-invasive urothelial bladder carcinoma (MIBC). We herein present survival outcomes after a median follow-up of three years. Patients and Methods: intention-to-treat (ITT) population included 155 patients. Event-free (EFS) was defined as time from pembrolizumab initiation until radiographic disease progression precluding...
Abstract Checkpoint immunotherapy (CPI) has increased survival for some patients with advanced-stage bladder cancer (BCa). However, most do not respond. Here, we characterized the tumor and immune microenvironment in pre- post-treatment tumors from PURE01 neoadjuvant pembrolizumab trial, using a consolidative approach that combined transcriptional genetic profiling digital spatial profiling. We identify five distinctive transcriptomic programs validate these an independent CPI trial to...
•The PURE-01 study tested neoadjuvant pembrolizumab in patients with muscle invasive bladder cancer.•Pembrolizumab has shown promising activity this setting, reaching 38.5% of complete response (ypT0ypN0).•Event-free survival is also encouraging 84.5% and 71.7% rates at 12 24 months from immunotherapy initiation.•Survival benefit seems spread to all pathological subgroups the exception ypN+ patients.•Molecular subtyping may be a useful tool select who are predicted most pembrolizumab....
Neoadjuvant pembrolizumab has been shown to be a valid treatment for patients affected by muscle-invasive bladder cancer (MIBC), as demonstrated in the PURE-01 clinical trial (NCT02736266). Among tumor-extrinsic factors influencing immunotherapy efficacy, extensive data highlighted that microbiome is central player immune-mediated anticancer activity. This report aimed investigate composition and role of stool enrolled trial. An orthotopic animal model (MB49-Luc) was used support some...
To assess time trends in the inclusion of health-related quality life (QoL) among study endpoints and reporting QoL results publications, randomised phase III oncology trials published between 2017 2021 were compared with previous 5 years. All issues 2012 by 11 major journals handsearched for primary publications adult patients solid tumours. Trials 2017-2021 2012-2016 three endpoints: (1) proportion including out all eligible publications; (2) presenting those (3) data publications. 388 446...
Renal tumour biopsy (RTB) can help in risk stratification of renal tumours with implications for management, but its utilisation varies. Our objective was to report current practice patterns, experiences, and perceptions RTB research gaps regarding small masses (SRMs).
Abstract Background In the PURE-01 study (NCT02736266), we aimed to evaluate ability predict pathologic complete response (pT0N0) after pembrolizumab by using clinical and tumor biomarkers. Methods an open-label, single-arm, phase 2 study, 3 courses of 200 mg preceding radical cystectomy were administered in patients with T2-4aN0M0 muscle-invasive bladder cancer. The analyses included a comprehensive genomic profiling programmed cell-death-ligand-1 (PD-L1)–combined positive score assessment...